* Subject to discussion with FDA, the clinical development programs will begin with Phase 2 studies supported by the Phase 1 AD studies
Cognition has identified several compounds that bind to a receptor that regulates the cellular damage response and have shown potential in the treatment of Alzheimer’s and Parkinson’s diseases. The company’s lead candidate, CT1812, is a first-in-class, orally dosed and highly brain penetrant small molecule that is being assessed as a treatment for mild-to-moderate Alzheimer’s disease. Several studies designed to assess the safety, efficacy and mechanism of action of CT1812 are underway and planned.
Beginning in 2021, Cognition intends to study CT1812 in indications beyond Alzheimer’s disease, including dry AMD.